Literature DB >> 11351042

Increases in renal epsilon-(gamma-glutamyl)-lysine crosslinks result from compartment-specific changes in tissue transglutaminase in early experimental diabetic nephropathy: pathologic implications.

N J Skill1, M Griffin, A M El Nahas, T Sanai, J L Haylor, M Fisher, M F Jamie, N N Mould, T S Johnson.   

Abstract

Diabetic nephropathy (DN) is characterized by an early, progressive expansion and sclerosis of the glomerular mesangium leading to glomerulosclerosis. This is associated with parallel fibrosis of the renal interstitium. In experimental renal scarring, the protein cross-linking enzyme, tissue transglutaminase (tTg), is up-regulated and externalized causing an increase in its crosslink product, epsilon-(gamma-glutamyl)-lysine, in the extracellular space. This potentially contributes to the extracellular matrix (ECM) accumulation central to tissue fibrosis by increasing deposition and inhibiting breakdown. We investigated if a similar mechanism may contribute to the ECM expansion characteristic of DN using the rat streptozotocin model over 120 days. Whole kidney epsilon-(gamma-glutamyl)-lysine (HPLC analysis) was significantly increased from Day 90 (+337%) and peaked at Day 120 (+650%) (p < 0.05). Immunofluorescence showed this increase to be predominantly extracellular in the peritubular interstitial space, but also in individual glomeruli. Total kidney transglutaminase (Tg) was not elevated. However, using a Tg in situ activity assay, increased Tg was detected in both the extracellular interstitial space and glomeruli by Day 60, with a maximal 53% increase at Day 120 (p < 0.05). Using a specific anti-tTg antibody, immunohistochemistry showed a similar increase in extracellular enzyme in the interstitium and glomeruli. To biochemically characterize glomerular changes, glomeruli were isolated by selective sieving. In line with whole kidney measurement, there was an increase in glomerular epsilon-(gamma-glutamyl) lysine (+361%); however, in the glomeruli this was associated with increases in Tg activity (+228%) and tTg antigen by Western blotting (+215%). Importantly, the ratio of glomerular epsilon-(gamma-glutamyl) lysine to hydroxyproline increased by 2.2-fold. In DN, changes in the kidney result in increased translocation of tTg to the extracellular environment where high Ca(2+) and low GTP levels allow its activation. In the tubulointerstitium this is independent of increased tTg production, but dependent in the glomerulus. This leads to excessive ECM cross-linking, contributing to the renal fibrosis characteristic of progressive DN.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11351042     DOI: 10.1038/labinvest.3780279

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  15 in total

1.  Tissue transglutaminase inhibits the TRPV5-dependent calcium transport in an N-glycosylation-dependent manner.

Authors:  Sandor Boros; Qi Xi; Henrik Dimke; Annemiete W van der Kemp; Kukiat Tudpor; Sjoerd Verkaart; Kyu Pil Lee; René J Bindels; Joost G Hoenderop
Journal:  Cell Mol Life Sci       Date:  2011-09-28       Impact factor: 9.261

2.  A crucial sequence for transglutaminase type 2 extracellular trafficking in renal tubular epithelial cells lies in its N-terminal beta-sandwich domain.

Authors:  Che-Yi Chou; Andrew J Streets; Philip F Watson; Linghong Huang; Elisabetta A M Verderio; Timothy S Johnson
Journal:  J Biol Chem       Date:  2011-06-07       Impact factor: 5.157

3.  (99m)Tc-NC100668, a new tracer for imaging venous thromboemboli: pre-clinical biodistribution and incorporation into plasma clots in vivo and in vitro.

Authors:  David Edwards; Joanne Lewis; Mark Battle; Rochelle Lear; Gill Farrar; D Jon Barnett; Vanessa Godden; Alexandra Oliveira; Catherine Coombes; Håkan Ahlström
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-06-28       Impact factor: 9.236

4.  Syndecan-4 knockout leads to reduced extracellular transglutaminase-2 and protects against tubulointerstitial fibrosis.

Authors:  Alessandra Scarpellini; Linghong Huang; Izhar Burhan; Nina Schroeder; Muriel Funck; Timothy S Johnson; Elisabetta A M Verderio
Journal:  J Am Soc Nephrol       Date:  2013-12-19       Impact factor: 10.121

Review 5.  Transglutaminse 2 and EGGL, the protein cross-link formed by transglutaminse 2, as therapeutic targets for disabilities of old age.

Authors:  William Bains
Journal:  Rejuvenation Res       Date:  2013-12       Impact factor: 4.663

6.  Tissue transglutaminase contributes to interstitial renal fibrosis by favoring accumulation of fibrillar collagen through TGF-beta activation and cell infiltration.

Authors:  Nasim Shweke; Nada Boulos; Chantal Jouanneau; Sophie Vandermeersch; Gerry Melino; Jean-Claude Dussaule; Christos Chatziantoniou; Pierre Ronco; Jean-Jacques Boffa
Journal:  Am J Pathol       Date:  2008-08-07       Impact factor: 4.307

7.  Tissue transglutaminase inhibition as treatment for diabetic glomerular scarring: it's good to be glueless.

Authors:  Jeffrey R Schelling
Journal:  Kidney Int       Date:  2009-08       Impact factor: 10.612

8.  Proteomic Profiling Reveals the Transglutaminase-2 Externalization Pathway in Kidneys after Unilateral Ureteric Obstruction.

Authors:  Giulia Furini; Nina Schroeder; Linghong Huang; David Boocock; Alessandra Scarpellini; Clare Coveney; Elisa Tonoli; Raghavendran Ramaswamy; Graham Ball; Claudia Verderio; Timothy S Johnson; Elisabetta A M Verderio
Journal:  J Am Soc Nephrol       Date:  2018-01-30       Impact factor: 10.121

9.  Advanced glycation end products increase transglutaminase activity in primary porcine tenocytes.

Authors:  Ann K Rosenthal; Claudia M Gohr; Elizabeth Mitton; Vincent Monnier; Todd Burner
Journal:  J Investig Med       Date:  2009-02       Impact factor: 2.895

10.  Increase in extracellular cross-linking by tissue transglutaminase and reduction in expression of MMP-9 contribute differentially to focal segmental glomerulosclerosis in rats.

Authors:  Senyan Liu; Yuehong Li; Huiying Zhao; Dong Chen; Qiang Huang; Suxia Wang; Wanzhong Zou; Youkang Zhang; Xiaomei Li; Haichang Huang
Journal:  Mol Cell Biochem       Date:  2006-02-14       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.